Pharmacokinetics of telbivudine in healthy subjects and absence of drug interaction with lamivudine or adefovir dipivoxil

Antimicrobial Agents and Chemotherapy

Volumn 50, Issue 7, 2006, Pages 2309-2315

  Zhou, Xiao Jian ^a   Fielman, Barbara A ^a   Lloyd, Deborah M ^a   Chao, George C ^a   Brown, Nathaniel A ^a  

^a Idenix Pharmaceuticals Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADEFOVIR DIPIVOXIL; LAMIVUDINE; TELBIVUDINE;

ADULT; AREA UNDER THE CURVE; ARTHRALGIA; ARTICLE; CLINICAL TRIAL; CONFIDENCE INTERVAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIZZINESS; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG TOLERABILITY; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; MALE; NAUSEA; NORMAL HUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SINGLE DRUG DOSE; STEADY STATE;

ADENINE; ADMINISTRATION, ORAL; ADULT; ANTI-HIV AGENTS; ANTIVIRAL AGENTS; AREA UNDER CURVE; DRUG INTERACTIONS; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; LAMIVUDINE; MALE; MIDDLE AGED; NUCLEOSIDES; PHOSPHONIC ACIDS; PYRIMIDINONES; REVERSE TRANSCRIPTASE INHIBITORS;

EID: 33745584135     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.01313-05     Document Type: Article

References (23)

1. Bryant, M. L., E. G. Bridges, L. Placidi, A. Faraj, A.-G. Loi, C. Pierra, D. Dukhan, G. Gosselin, J.-L. Imbach, B. Hernandez, A. Juodawlkis, B. Tennant, B. Korba, P. Cote, P. Marion, E. Cretton-Scott, R. F. Schinazi, and J.-P. Sommadossi. 2001. Antiviral L-nucleosides specific for hepatitis B virus infection. Antimicrob. Agents Chemother. 45:229-235.
2. Chan, H. L., N. W. Leung, A. Y. Hui, V. W. Wong, C. T. Liew, A. M. L. Chim, F. K. Chan, L. C. Hung, Y. T. Lee, J. S. Tam, C. W. Lam, and J. J. Sung. 2005. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-α2b and lamivudine with lamivudine alone. Ann. Intern. Med. 142:240-250.
3. Colledge, D., G. Civitico, S. Locarnini, and T. Shaw. 2000. In vitro anti-hepadnaviral activities of combinations of penciclovir, lamivudine, and adefovir. Antimicrob. Agents Chemother. 44:551-560.
4. Cundy, K. C. 1999. Clinical pharmacokinetics of the antiviral nucleotide analogues cidofovir and adefovir. Clin. Pharmacokinet. 36:127-143.
5. Dando, T. M., and G. Plosker. 2003. Adefovir dipivoxil: a review of its use in chronic hepatitis B. Drugs 63:2215-2234.
6. Delaney, W. E., IV, H. Yang, M. D. Miller, C. S. Gibbs, and S. Xiong. 2004. Combinations of adefovir with nucleoside analogs produce additive antiviral effects against hepatitis B virus in vitro. Antimicrob. Agents Chemother. 48:3702-3710.
7. Ghany, M. G., and E. C. Doo. 2004. Management of chronic hepatitis B. Gastroenterol. Clin. N. Am. 33:563-579.
8. Gibaldi, M., and D. Perrier. 1982. Multiple dosing, p. 113-144. In J. Swarbrick (ed.), Drugs and the pharmaceutical sciences, vol. 15, 2nd ed. Marcel Dekker, Inc., New York, N.Y.
9. Janssen, H. L. A., M. van Zonneveld, H. Senturk, S. Zeuzem, U. S. Akarca, Y. Cakaloglu, C. Simon, T. M. K. So, G. Gerken, R. A. De Man, H. G. M. Niesters, P. Zondervan, B. Hansen, S. W. Schalm, et al. 2005. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 365:123-129.
10. Johnson, M. A., K. H. Moore, G. J. Yuen, A. Bye, and G. E. Pakes. 1999. Clinical pharmacokinetics of lamivudine. Clin. Pharmacokinet. 36:41-66.
11. Korba, B. E., P. Cote, W. Hornbuckle, R. Schinazi, J. D. Gangemi, B. C. Tennant, and J. L. Gerin. 2000. Enhanced antiviral benefit of combination therapy with lamivudine and alpha interferon against WHV replication in chronic carrier woodchucks. Antivir. Ther. 5:95-104.
12. Lai, C. L., N. W. Y. Leung, E. K. Teo, M. Tong, F. Wong, H. W. Hann, S. Han, T. Poynard, M. Myers, G. Chao, D. Lloyd, N. Brown, et al. 2005. A 1-year trial of telbivudine, lamivudine, and the combination in patients with hepatitis B e antigen-positive chronic hepatitis B. Gastroenterology 129:528-536.
13. Lai, C. L., S. G. Lim, N. A. Brown, X. J. Zhou, D. M. Lloyd, Y. M. Lee, M. F. Yuen, G. C. Chao, and. M. W. Myers. 2004. A dose-finding study of once-daily oral telbivudine in HBeAg-positive patients with chronic hepatitis B virus infection. Hepatology 40:719-726.
14. Lok, A. S. F. 2004. New treatment of hepatitis B. Semin. Liver Dis. 24(Suppl. 1):77-82.
15. Lok, A. S. F., and B. J. McMahon. 2004. Chronic hepatitis B: update of recommendations. Hepatology 39:857-861.
16. Marcellin, P., G. K. K. Lau, F. Bonino, P. Farci, S. Hadziyannis, R. Jin, Z.-M. Lu, T. Piratvisuth, G. Germanidis, C. Yurdaydin, M. Diago, S. Gurel, M.-Y. Lai, P. Button, N. Pluck, et al. 2004. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N. Engl. J. Med. 351:1206-1217.
17. Menne, S., C. A. Roneker, B. C. Tennant, B. E. Korba, J. L. Gerin, and P. J. Cote. 2002. Immunogenic effects of woodchuck hepatitis virus surface antigen vaccine in combination with antiviral therapy: breaking of humoral and cellular immune tolerance in chronic woodchuck hepatitis virus infection. Intervirology 45:237-250.
18. Perillo, R. P. 2004. Overview of treatment of hepatitis B: key approaches and clinical challenges. Semin. Liver Dis. 24(Suppl. 1):23-29.
19. Seignères, B., P. Martin, B. Werle, O. Schorr, C. Jamard, L. Rimsky, C. Trépo, and F. Zoulim. 2003. Effects of pyrimidine and purine analog combinations in the duck hepatitis B virus infection model. Antimicrob. Agents Chemother. 47:1842-1852.
20. U.S. Food and Drug Administration. 2005. CDER drug and biologic approvals for calendar year 2005. [Online.] http://www.fda.gov/cder/rdmt/ndaaps05cy.htm.
21. Zhou, X. J., S. G. Lim, D. M. Lloyd, G. C. Chao, N. A. Brown, and C. L. Lai. 2006. Pharmacokinetics of telbivudine following oral administration of escalating single and multiple doses in patients with chronic hepatitis B virus infection: pharmacodynamic implications. Antimicrob. Agents Chemother. 50:874-879.
22. Zhou, X. J., S. G. Lim, C. L. Lai, D. M. Pow, N. A. Brown, and M. W. Myers. 2001. Pharmacokinetics of β-L-deoxythymidine (LdT) in healthy subjects and patients with chronic hepatitis B virus infection, p. 92, abstr. 100. HEP DART 2001. Frontiers in Drug Development for Viral Hepatitis. Elsevier Science B.V., Amsterdam, The Netherlands.
23. Zhou, X. J., M. Myers, G. Chao, G. Dubuc, and N. A. Brown. 2004. Clinical pharmacokinetics of telbivudine, a potent antiviral for hepatitis B, in subjects with impaired hepatic or renal function. 55th Annu. Meet. Am. Assoc. Study Liver Dis., abstr. 1166. Hepatology 40(Suppl. 1):672A.